Cargando…

Efficacy of anti‐severe acute respiratory syndrome coronavirus 2 mRNA vaccines in adults with severe acquired aplastic anemia with or without allogeneic hematopoietic stem cell transplantation

Detalles Bibliográficos
Autores principales:	Garnier, Alice, Bourgeois, Amandine Le, Guillaume, Thierry, Peterlin, Pierre, Jullien, Maxime, Coste‐Burel, Marianne, Béné, Marie C, Chevallier, Patrice
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885527/ https://www.ncbi.nlm.nih.gov/pubmed/36733664 http://dx.doi.org/10.1002/jha2.570

Ejemplares similares

Efficacy of Anti-Sars-Cov-2 mRNA Vaccines in Adults with Severe Acquired Aplastic Anemia with or without Allograft
por: Garnier, Alice, et al.
Publicado: (2022)

Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients
por: Clémenceau, Béatrice, et al.
Publicado: (2022)

Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
por: Le Bourgeois, Amandine, et al.
Publicado: (2021)

Incidence and Severity of COVID-19 Infections in a Cohort of 211 Allotransplanted Patients after One or Two Boosters during the Omicron Wave in France
por: Letailleur, Valentin, et al.
Publicado: (2022)

Assessment of COVID-19 Incidence and Severity Among Recipients of Allogenic Stem Cell Transplant After 1 or 2 mRNA Booster Doses During the Omicron Wave in France
por: Letailleur, Valentin, et al.
Publicado: (2022)

Sars-Cov-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Transplant Recipients
por: Clemenceau, Beatrice, et al.
Publicado: (2022)

SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA Vaccine
por: Clémenceau, Béatrice, et al.
Publicado: (2022)

Assessment of monocytic‐myeloid‐derived suppressive cells (M‐MDSC) before and after allogeneic hematopoietic stem cell transplantation in acute leukemia patients
por: Peterlin, Pierre, et al.
Publicado: (2023)

Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients
por: Chevallier, Patrice, et al.
Publicado: (2021)

Interest of a Third Dose of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Stem-Cells Recipients
por: Le Bourgeois, Amandine, et al.
Publicado: (2021)

Post‐transplant cyclophosphamide as sole GHVD prophylaxis after matched reduced‐intensity conditioning allotransplant
por: Bourgeois, Amandine Le, et al.
Publicado: (2023)

B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
por: Jullien, Maxime, et al.
Publicado: (2022)

Sars-Cov-2 T-Cell Response in Allogeneic Hematopoietic Stem Cell Recipients Following Two Doses of BNT162b2 Vaccine
por: Clemenceau, Beatrice, et al.
Publicado: (2021)

Profound B-Cell Lymphopenia Is a Major Factor Predicting Poor Humoral Response after BNT162b2 mRNA Sars-Cov-2 Vaccines in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
por: Jullien, Maxime, et al.
Publicado: (2021)

Peripheral levels of monocytic myeloid‐derived suppressive cells before and after first induction predict relapse and survivals in AML patients
por: Peterlin, Pierre, et al.
Publicado: (2022)

Anti‐SARS‐CoV‐2 vaccines in recipient and/or donor before allotransplant
por: Jullien, Maxime, et al.
Publicado: (2022)

P534: FIRST-IN-HUMAN TRIAL OF TOCILIZUMAB IN COMBINATION WITH A STANDARD INDUCTION CHEMOTHERAPY IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS: THE PHASE 1 TOCILAM STUDY.
por: Peterlin, Pierre, et al.
Publicado: (2023)

Haploidentical hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia
por: Im, Ho Joon, et al.
Publicado: (2015)

Allogeneic Hematopoietic Stem Cell Transplantation in Severe Aplastic Anemia: A Single Centre Experience in Malaysia
por: Wilfred, Gilbert, et al.
Publicado: (2022)

Recent advances and current challenges in allogeneic stem cell transplantation in patients with acquired severe aplastic anemia
por: Lee, Sung-Eun, et al.
Publicado: (2018)

Antibody Response after One and/or Two Doses of BNT162b2 Anti- Sars-Cov-2 mRNA Vaccine in Patients Treated By CAR T-Cells Therapy
por: Gastinne, Thomas, et al.
Publicado: (2021)

Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia
por: Eapen, Mary, et al.
Publicado: (2020)

Tocilizumab in combination with a standard induction chemotherapy in acute myeloid leukaemia patients (TOCILAM study): a single-centre, single-arm, phase 1 trial
por: Peterlin, Pierre, et al.
Publicado: (2023)

Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post‐transplant cyclophosphamide
por: Jullien, Maxime, et al.
Publicado: (2021)

Acquired Aplastic Anemia as a Clonal Disorder of Hematopoietic Stem Cells
por: Brzeźniakiewicz-Janus, Katarzyna, et al.
Publicado: (2020)

Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia
por: Lengline, Etienne, et al.
Publicado: (2018)

Hematopoietic stem cell transplantation for severe aplastic anemia—experience of an institute in Taiwan
por: Bai, L. Y., et al.
Publicado: (2003)

Immune Reconstitution in Pediatric Aplastic Anemia after Allogeneic Hematopoietic Stem-cell Transplantation
por: Wang, Jiayu, et al.
Publicado: (2022)

Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation
por: Mohanan, E, et al.
Publicado: (2017)

First-Line Matched Related Donor Hematopoietic Stem Cell Transplantation Compared to Immunosuppressive Therapy in Acquired Severe Aplastic Anemia
por: Peinemann, Frank, et al.
Publicado: (2011)

Optimal donor for severe aplastic anemia patient requiring allogeneic hematopoietic stem cell transplantation: A large-sample study from China
por: Zeng, Yunjing, et al.
Publicado: (2018)

Inefficacy of Immunosuppressive Therapy for Severe Aplastic Anemia Progressing From Non-SAA: Improved Outcome After Allogeneic Hematopoietic Stem Cell Transplantation
por: Liu, Limin, et al.
Publicado: (2021)

Co-occurrence of Multiple Sclerosis and Severe Aplastic Anemia: A Report of Two Cases Successfully Treated with Allogeneic Hematopoietic Stem Cell Transplantation
por: Haroon, Alfadil, et al.
Publicado: (2023)

The Impact of Eltrombopag Administration on the Clinical Course of Severe Refractory Fatal Acquired Aplastic Anemia
por: Işık, Ayşe, et al.
Publicado: (2013)

Correction: Population pharmacokinetics of fludarabine in patients with aplastic anemia and Fanconi anemia undergoing allogeneic hematopoietic stem cell transplantation
por: Mohanan, E., et al.
Publicado: (2018)

Hematopoietic stem cell loss and hematopoietic failure in severe aplastic anemia is driven by macrophages and aberrant podoplanin expression
por: McCabe, Amanda, et al.
Publicado: (2018)

Hematopoietic Stem-Cell Transplantation versus Immunosuppressive Therapy in Patients with Adult Acquired Severe Aplastic Anemia: A Cost-Effectiveness Analysis
por: Zhang, Meng-Xue, et al.
Publicado: (2021)

Severe Aplastic Anemia Presenting as Neutropenic Sepsis
por: Daniels, Natasha Faye, et al.
Publicado: (2020)

COVID-19 in children with severe aplastic anemia
por: Thakkar, Dhwanee, et al.
Publicado: (2022)

Massive eosinophilia despite severe aplastic anemia
por: Takahashi, Aya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_916cu6aka99ql4vjangkpa94aa